Evolent Health, Inc. (NYSE: EVH) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $515M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Evolent Health, Inc. had a Maz Rating of 2.83 out of 5 (C+, Hold), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.04), above most of its sector; its weakest was Financial Health (1.75), below most of its sector. The other factors: Momentum 3.47 (around the middle of its sector); Valuation 3.09 (valued in line with its sector); Growth 2.00 (below most of its sector). The current rating is for members: log in to see it.
At $4.58, Evolent Health, Inc. trades at 0.2x sales and 1.4x book value. Over the last twelve months it generated about $2.3B of revenue and a net loss of $502M. It runs a gross margin of 12.1%, an operating margin of -1.0% and a net margin of -21.7%. It shows return on equity of -129.5%, return on invested capital of -1.6% and a free cash flow yield of 7.1%. On the balance sheet: a debt-to-equity ratio of 2.61 and a current ratio of 1.26. Over the past 52 weeks the share price ranged from $2.10 to $6.26, with a beta of 0.84.
Evolent Health, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 23 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.